Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) announced plans to participate in four virtual investor conferences in February and March 2021. Key events include the Guggenheim Healthcare Talks on February 11, the Cowen 41st Annual Health Care Conference on March 3, the 33rd Annual Roth Conference on March 15, and Oppenheimer's 31st Annual Healthcare Conference on March 16. These events will showcase Allogene's progress in developing allogeneic CAR T therapies for cancer. Webcast details and replays will be available on the company's website.

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences.

Guggenheim Healthcare Talks 2021 Oncology Days
Thursday, February 11, 2021
6:30AM PT/9:30AM ET

Cowen 41st Annual Health Care Conference
Wednesday, March 3, 2021
11:40AM PT/2:40PM ET

33rd Annual Roth Conference
Monday, March 15, 2021
Presentation time to be determined

Oppenheimer's 31st Annual Healthcare Conference
Tuesday, March 16, 2021
10:50AM PT/1:50PM ET

Final presentation times and webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

What conferences will Allogene Therapeutics participate in during February and March 2021?

Allogene Therapeutics will participate in four virtual investor conferences: Guggenheim Healthcare Talks on February 11, Cowen 41st Annual Health Care Conference on March 3, 33rd Annual Roth Conference on March 15, and Oppenheimer's 31st Annual Healthcare Conference on March 16.

What is the focus of Allogene Therapeutics' presentations at the upcoming conferences?

The presentations will focus on Allogene's development of allogeneic CAR T therapies for cancer, specifically showcasing their advancements in this area.

Where can I find the webcast details for Allogene Therapeutics' conference presentations?

Webcast details and replays for Allogene's conference presentations will be available on their website under the Investors tab in the News and Events section.

What is AlloCAR T therapy developed by Allogene Therapeutics?

AlloCAR T therapy is an innovative treatment being developed by Allogene Therapeutics that involves the use of allogeneic chimeric antigen receptor T cells to target and treat cancer.

What date does Allogene plan to present at the Cowen 41st Annual Health Care Conference?

Allogene will present at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 AM PT.